Heart Failure Reviews

, Volume 15, Issue 4, pp 293–304 | Cite as

Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases



N-terminal fragment of pro B-type natriuretic peptide (NT-proBNP) has emerged as an important adjunct in the management of heart failure (HF) and other cardiovascular diseases. NT-proBNP is a 76-amino acid peptide created during cleavage of the precursor molecule, Pro B-type natriuretic peptide (ProBNP). NT-proBNP is of significant diagnostic value in patients presenting with possible HF and is an important prognostic factor in this condition and other cardiovascular diseases. Ongoing research supports the potential value of this biomarker in non-cardiovascular disease. This review will describe clinical applications of NT-proBNP in HF and a broad range of other conditions.


N-terminal pro B-type natriuretic peptide Heart failure Dyspnea 


  1. 1.
    Rehman SU, Januzzi JL (2008) Natriuretic peptide testing in clinical medicine. Cardiol Rev 16:240–249PubMedGoogle Scholar
  2. 2.
    Maisel A, Mueller C, Adams KF Jr, Anker SD, Aspromonte N, Cleland JGF, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock F, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10:824–839PubMedGoogle Scholar
  3. 3.
    Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Peruchoud AP (2007) The integration of BNP and NT-pro BNP into clinical medicine. Swiss Med Wkly 137:4–12PubMedGoogle Scholar
  4. 4.
    Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA (1995) The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214:1175–1183PubMedGoogle Scholar
  5. 5.
    Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG (1993) Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69:414–417PubMedGoogle Scholar
  6. 6.
    Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K (1995) Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 25:1105–1110PubMedGoogle Scholar
  7. 7.
    Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, Baughman KL, Boehmer JP, Deedwania P, Dunbar SB, Elkayam U, Gheorghiade M, Howlett JG, Konstam MA, Kronenberg MW, Massie BM, Mehra MR, Miller AB, Moser DK, Patterson JH, Rodeheffer RJ, Sackner-Bernstein J, Silver MA, Starling RC, Stevenson LW, Wagoner LE (2006) Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12:10–38Google Scholar
  8. 8.
    Elin RJ, Winter WE (2004) Laboratory and clinical aspects of B-type natriuretic peptides. Arch Pathol Lab Med 128:697–699PubMedGoogle Scholar
  9. 9.
    Goetze JP (2004) Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50:1503–1510PubMedGoogle Scholar
  10. 10.
    Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr (2008) Biology of the natriuretic peptides. Am J Cardiol 101(3A):3–8PubMedGoogle Scholar
  11. 11.
    Hawkridge AM, Heublein DM, Bergen HRIII, Cataliotti A, Burnett JC Jr, Muddiman DC (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102:17442–17447PubMedGoogle Scholar
  12. 12.
    Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071–1078PubMedGoogle Scholar
  13. 13.
    Almirez R, Protter AA (1999) Clearance of human brain natriuretic peptide in rabbits; Effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 289:976–980PubMedGoogle Scholar
  14. 14.
    Pemberton CJ, Johnson ML, Yandle TG, Espiner EA (2000) Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36:355–359PubMedGoogle Scholar
  15. 15.
    Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C (1993) Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76:91–96PubMedGoogle Scholar
  16. 16.
    Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H (1991) Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 69:1500–1506PubMedGoogle Scholar
  17. 17.
    Ordonez-Llanos J, Collinson PO, Christenson RH (2008) Amino-terminal pro–B-type natriuretic peptide: analytic considerations. Am J Cardiol 101(S):9A–15AGoogle Scholar
  18. 18.
    Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M (2004) Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-pro BNP) in frozen samples. Clin Chem Lab Med 42:942–944PubMedGoogle Scholar
  19. 19.
    Sigurdsson A, Swedberg K (1996) The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J 132(S):229–234PubMedGoogle Scholar
  20. 20.
    Houben AJ, van der Zander K, de Leeuw PW (2005) Vascular and renal actions of B-type natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 19:411–419PubMedGoogle Scholar
  21. 21.
    Publication Committee for VMAC Investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive HF: a randomized controlled trial. JAMA 287:1531–1540Google Scholar
  22. 22.
    Krum H, Gilbert RE (2003) Demographics and concomitant disorders in heart failure. Lancet 362:147–158PubMedGoogle Scholar
  23. 23.
    Ahmed A, Allman RM, Aronow WS, DeLong JF (2004) Diagnosis of heart failure in older adults: predictive value of dyspnea at rest. Arch Gerontol Geriatr 38:297–307PubMedGoogle Scholar
  24. 24.
    Silver MA, Pisano C (2003) High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congest Heart Fail 9:127–132PubMedGoogle Scholar
  25. 25.
    Ghitelman J, Krumerman D, Latif F, Le Jemtel TH (2004) Serum brain natriuretic peptide level in a patient with chronic obstructive pulmonary disease and chronic heart failure. Congest Heart Fail 10:106–108PubMedGoogle Scholar
  26. 26.
    Barcarse E, Kazanegra R, Chen A, Chiu A, Clopton P, Maisel A (2004) Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department. Congest Heart Fail 10:171–176PubMedGoogle Scholar
  27. 27.
    Yang YJ, Mao Y, Ni XH, Chen JL, Gao RL, Chen ZJ (2007) The predictive value of B-type natriuretic peptide for the mortality from acute myocardial infarction. Zhonghua Nei Ke Za Zhi 46:450–453PubMedGoogle Scholar
  28. 28.
    Sinclair H, Paterson M, Walker S, Beckett G, Fox KA (2007) Predicting outcome in patients with acute coronary syndrome: evaluation of B-type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score. Scott Med J 52:8–13PubMedGoogle Scholar
  29. 29.
    Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S (2008) Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail 14:687–694PubMedGoogle Scholar
  30. 30.
    Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954PubMedGoogle Scholar
  31. 31.
    Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM (2003) Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42:728–735PubMedGoogle Scholar
  32. 32.
    Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR (2005) The diagnostic accuracy of plasma BNP and NT-pro BNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7:537–541PubMedGoogle Scholar
  33. 33.
    Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F (2004) Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90:297–303PubMedGoogle Scholar
  34. 34.
    Hildebrandt P, Collinson PO (2008) Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 101:25A–28AGoogle Scholar
  35. 35.
    Nielsen OW, McDonagh TA, Robb SD, Dargie HJ (2003) Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41:113–120PubMedGoogle Scholar
  36. 36.
    Hildebrandt P, Richards AM (2008) Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 101:21A–24AGoogle Scholar
  37. 37.
    Gustafsson F, Steensgaard-Hansen F, Badskjær J, Poulsen AH, Corell P, Hildebrandt P (2005) Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 11:S15–S20PubMedGoogle Scholar
  38. 38.
    Hill SA, Balion CM, Santaguida P, McQueen MJ, Ismaila AS, Reichert SM, McKelvie R, Worster A, Raina PS (2008) Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clin Biochem 41:240–249PubMedGoogle Scholar
  39. 39.
    De Lemos JA, Hildebrandt P (2008) Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 101:16A–20AGoogle Scholar
  40. 40.
    Spevack DM, Bowers J, Banerjee A, Talreja A, Altman EJ, Friedman MA, Bloom M, Malhotra D, Goldberg Y, Patel K, Spindola-Franco H (2008) Diagnostic accuracy of Doppler echocardiography for determining left ventricular diastolic pressure elevation: prospective comparison to chest radiography, serum B-type natriuretic peptide, and chest auscultation. Echocardiography 25:946–954PubMedGoogle Scholar
  41. 41.
    Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41:2010–2017PubMedGoogle Scholar
  42. 42.
    Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M (2006) NT-pro BNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-pro BNP Study. Eur Heart J 27:330–337PubMedGoogle Scholar
  43. 43.
    Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47:742–748PubMedGoogle Scholar
  44. 44.
    Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, Takano T (2004) Application of NT-pro BNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6:295–300PubMedGoogle Scholar
  45. 45.
    Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2004) Head-to-head comparison of the diagnostic utility of BNP and NT-pro BNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341:41–48PubMedGoogle Scholar
  46. 46.
    Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L (2006) Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 39:640–645PubMedGoogle Scholar
  47. 47.
    Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194–202PubMedGoogle Scholar
  48. 48.
    Ceyhan C, Unal S, Yenisey C, Tekten T, Ceyhan FB (2008) The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients. Int J Cardiovasc Imaging 24:253–259PubMedGoogle Scholar
  49. 49.
    Knebel F, Eddicks S, Schimke I, Bierbaum M, Schattke S, Beling M, Raab V, Baumann G, Borges AC (2008) Myocardial tissue Doppler echocardiography and N-terminal B-type natriuretic peptide (NT-pro BNP) in diastolic and systolic heart failure. Cardiovasc Ultrasound 6:45PubMedGoogle Scholar
  50. 50.
    Hettwer S, Panzner-Grote B, Witthaut R, Werdan K (2007) Isolated diastolic dysfunction—diagnostic value of tissue Doppler imaging, color M-mode and N-terminal pro B-type natriuretic peptide. Clin Res Cardiol 96:874–882PubMedGoogle Scholar
  51. 51.
    Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS, Investigators of the CHARM Echocardiographic Substudy-CHARMES (2007) Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49:687–694PubMedGoogle Scholar
  52. 52.
    Grewal J, McKelvie R, Lonn E, Tait P, Carlsson J, Gianni M, Jarnert C, Persson H (2008) BNP and NT-pro BNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail 10:252–259PubMedGoogle Scholar
  53. 53.
    Grewal J, McKelvie R, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E (2008) Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 102:733–737PubMedGoogle Scholar
  54. 54.
    Baggish AL, van Kimmenade RR, Januzzi JL Jr (2008) Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. Am J Cardiol 101:49–55PubMedGoogle Scholar
  55. 55.
    Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R (2008) Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 10:404–411PubMedGoogle Scholar
  56. 56.
    Bruch C, Rothenburger M, Gotzmann M, Sindermann J, Scheld HH, Breithardt G, Wichter T (2006) Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment. J Am Soc Echocardiogr 19:522–528PubMedGoogle Scholar
  57. 57.
    Ferreira S, Almeida R, Guerrero H, Lourenço-Ferreira S, Fonseca L, Rocha R, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2007) Prognosis of decompensated heart failure: role of NT-pro BNP. Rev Port Cardiol 26:535–545PubMedGoogle Scholar
  58. 58.
    Alehagen U, Lindstedt G, Levin LA, Dahlström U (2005) Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 100:125–133PubMedGoogle Scholar
  59. 59.
    Lim TK, Hayat SA, Gaze D, Celik E, Collinson P, Senior R (2007) Independent value of echocardiography and N-terminal pro-natriuretic peptide for the prediction of major outcomes in patients with suspected heart failure. Am J Cardiol 100:870–875PubMedGoogle Scholar
  60. 60.
    Rosenberg J, Schou M, Gustafsson F, Badskjær J, Hildebrandt P (2009) Prognostic threshold levels of NT-pro BNP testing in primary care. Eur Heart J 30:66–73PubMedGoogle Scholar
  61. 61.
    Nicholls MG, Frampton CM, Yandle TG (2008) BNP: not just for heart failure. Heart 94:6–7PubMedGoogle Scholar
  62. 62.
    Zeller M, Cottin Y, Laurent Y, Danchin N, L’Huillier I, Collin B, Desgrés J, Ravisy J, Janin-Manificat L, Makki H, Jolak M, Beer JC, Dentan G, Gambert P, Wolf JE (2004) N-terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Cardiology 102:37–40PubMedGoogle Scholar
  63. 63.
    Wolber T, Maeder M, Rickli H, Riesen W, Binggeli C, Duru F, Ammann P (2007) N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis. Eur J Clin Invest 37:18–25PubMedGoogle Scholar
  64. 64.
    Foote RS, Pearlman JD, Siegel AH, Yeo KT (2004) Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44:1980–1987PubMedGoogle Scholar
  65. 65.
    Weber M, Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A, Mitrovic V, Hamm C (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-pro BNP) in acute coronary syndromes. Clin Res Cardiol 95:270–280PubMedGoogle Scholar
  66. 66.
    Marumoto K, Hamada M, Hiwada K (1995) Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 88:551–556Google Scholar
  67. 67.
    Maewal P, de Lemos JA (2003) Natriuretic peptide hormone measurement in acute coronary syndromes. Heart Fail Rev 8:365–368PubMedGoogle Scholar
  68. 68.
    McClure SJ, Gall S, Schechter CB, Kearney M, Zaman AG (2007) Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease. J Am Coll Cardiol 49:2394–2397PubMedGoogle Scholar
  69. 69.
    Tateishi J, Masutani M, Ohyanagi M, Iwasaki T (2000) Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 23:776–780PubMedGoogle Scholar
  70. 70.
    Nakamura S, Naruse M, Naruse K, Kawana M, Nishikawa T, Hosoda S, Tanaka I, Yoshimi T, Yoshihara I, Inagami T et al (1991) Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 4:909–912PubMedGoogle Scholar
  71. 71.
    Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91PubMedGoogle Scholar
  72. 72.
    Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921–1929PubMedGoogle Scholar
  73. 73.
    Khan SQ, Quinn P, Davies JE, Ng LL (2008) N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 94:40–43PubMedGoogle Scholar
  74. 74.
    Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212PubMedGoogle Scholar
  75. 75.
    Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald E, A to Z Investigators (2005) Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294:2866–2871PubMedGoogle Scholar
  76. 76.
    Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA (2007) N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-pro BNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297:169–176PubMedGoogle Scholar
  77. 77.
    Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, PEACE Investigators (2007) Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 50:205–214PubMedGoogle Scholar
  78. 78.
    Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J (2005) Plasma NT-pro BNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press 14:99–106PubMedGoogle Scholar
  79. 79.
    Montagnana M, Lippi G, Fava C, Minuz P, Santonastaso CL, Arosio E, Guidi GC (2006) Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease. Clin Chem Lab Med 44:207–212PubMedGoogle Scholar
  80. 80.
    Mueller T, Dieplinger B, Poelz W, Endler G, Wagner OF, Haltmayer M (2009) Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study. Clin Chem 55:68–77PubMedGoogle Scholar
  81. 81.
    Vartany E, Imevbore M, O’Malley M, Manfredi C, Pasquarella C, Scinto L, Fine J (2006) N-terminal pro-brain natriuretic peptide for detection of cardiovascular stress in patients with obstructive sleep apnea syndrome. J Sleep Res 15:424–429PubMedGoogle Scholar
  82. 82.
    Choi HJ, Shin YK, Lee HJ, Kee JY, Shin DW, Lee EY, Lee YJ, Lee EB, Song YW (2008) The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 27:437–442PubMedGoogle Scholar
  83. 83.
    Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, Uckan A, Kosar F (2007) Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 22:2992–2998PubMedGoogle Scholar
  84. 84.
    Nasser N, Perles Z, Rein AJ, Nir A (2006) NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 27:87–90PubMedGoogle Scholar
  85. 85.
    Avello N, Molina BD, Llorente E, Bernardo MJ, Prieto B, Alvarez FV (2007) N-terminal pro-brain natriuretic peptide as a potential non-invasive marker of cardiac transplantation rejection. Ann Clin Biochem 44:182–188PubMedGoogle Scholar
  86. 86.
    Cuppoletti A, Roig E, Pérez-Villa F, Marin JL, Orús J, Vallejos I, Rivera A, Botta C (2005) Value of NT-proBNP determinations in the follow-up of heart transplantation. Transplant Proc 37:4033–4035PubMedGoogle Scholar
  87. 87.
    Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52:1511–1517PubMedGoogle Scholar
  88. 88.
    Raedle-Hurst TM, Welsch C, Forestier N, Kronenberger B, Hess G, Herrmann E, Zeuzem S, Raedle J (2008) Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. Eur J Gastroenterol Hepatol 20:865–873PubMedGoogle Scholar
  89. 89.
    Morello A, Lloyd-Jones DM, Chae CU, van Kimmenade RR, Chen AC, Baggish AL, O’Donoghue M, Lee-Lewandrowski E, Januzzi JL Jr (2007) Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 153:90–97PubMedGoogle Scholar
  90. 90.
    Della Corte A, Salerno G, Chiosi E, Iarussi D, Santarpino G, Miraglia M, Naviglio S, De Feo M (2008) Preoperative, postoperative and 1-year follow-up N-terminal pro-B-type natriuretic peptide levels in severe chronic aortic regurgitation: correlations with echocardiographic findings. Interact Cardiovasc Thorac Surg 7:419–424PubMedGoogle Scholar
  91. 91.
    Davutoglu V, Celik A, Aksoy M, Sezen Y, Soydinc S, Gunay N (2005) Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. Eur J Heart Fail 7:532–536PubMedGoogle Scholar
  92. 92.
    Weber M, Hausen M, Arnold R, Nef H, Moellman H, Berkowitsch A, Elsaesser A, Brandt R, Mitrovic V, Hamm C (2006) Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92:1639–1644PubMedGoogle Scholar
  93. 93.
    Dini FL, Fontanive P, Conti U, Andreini D, Cabani E, De Tommasi SM (2008) Plasma N-terminal protype-B natriuretic peptide levels in risk assessment of patients with mitral regurgitation secondary to ischemic and nonischemic dilated cardiomyopathy. Am Heart J 155:1121–1127PubMedGoogle Scholar
  94. 94.
    Dini FL, Fontanive P, Panicucci E, Andreini D, Chella P, De Tommasi SM (2008) Prognostic significance of tricuspid annular motion and plasma NT-proBNP in patients with heart failure and moderate-to-severe functional mitral regurgitation. Eur J Heart Fail 10:573–580PubMedGoogle Scholar
  95. 95.
    Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, Jensen GB (2007) Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 108:35–39PubMedGoogle Scholar
  96. 96.
    Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG (2006) The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J 10:573–580Google Scholar
  97. 97.
    Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313–1321PubMedGoogle Scholar
  98. 98.
    Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T (2006) N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98:525–529PubMedGoogle Scholar
  99. 99.
    Suntharalingam J, Goldsmith K, Toshner M, Doughty N, Sheares KK, Hughes R, Jenkins D, Pepke-Zaba J (2007) Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med 101:2254–2262PubMedGoogle Scholar
  100. 100.
    Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E (2008) Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52:450–459PubMedGoogle Scholar
  101. 101.
    Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2008) Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 26:26–34PubMedGoogle Scholar
  102. 102.
    Valle R, Aspromonte N, Barro S, Canali C, Carbonieri E, Ceci V, Chinellato M, Gallo G, Giovinazzo P, Ricci R, Milani L (2005) The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail 7:542–551PubMedGoogle Scholar
  103. 103.
    Beer S, Golay S, Bardy D, Feihl F, Gaillard RC, Bachmann C, Waeber B, Ruiz J (2005) Increased plasma levels of N-terminal brain natriuretic peptide (NT-pro BNP) in type 2 diabetic patients with vascular complications. Diabetes Metab 31:567–573PubMedGoogle Scholar
  104. 104.
    Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry RR, Maisel AS (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44:1047–1052PubMedGoogle Scholar
  105. 105.
    Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH (2006) Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49:2256–2262PubMedGoogle Scholar
  106. 106.
    Wang AY, Lai KN (2008) Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 19:1643–1652PubMedGoogle Scholar
  107. 107.
    Clerico A, Caprioli R, Del Ry S, Giannessi D (2001) Cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 24:24–30PubMedGoogle Scholar
  108. 108.
    Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS, CREED Investigators. The Cardiovascular Risk Extended Evaluation (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59:1559–1566PubMedGoogle Scholar
  109. 109.
    Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, Minami J, Honda T, Uetake S, Asakawa H, Kobayashi N, Horinaka S, Ishimitsu T, Matsuoka H (2001) Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 37:1201–1208PubMedGoogle Scholar
  110. 110.
    Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL (2006) Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 126:506–512PubMedGoogle Scholar
  111. 111.
    Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS, Creed Investigators (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508–1515PubMedGoogle Scholar
  112. 112.
    Apple FS, Murakami MM, Pearce LA, Herzog CA (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50:2279–2285PubMedGoogle Scholar
  113. 113.
    Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47:91–97PubMedGoogle Scholar
  114. 114.
    Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R (2008) Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 102:469–474PubMedGoogle Scholar
  115. 115.
    van Kimmenade RR, Pinto Y, Januzzi JL Jr (2007) When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the ‘cardio-renal syndrome’? Eur Heart J 28:2960–2961PubMedGoogle Scholar
  116. 116.
    Bodlaj G, Pichler R, Brandstätter W, Hatzl-Griesenhofer M, Maschek W, Biesenbach G, Berg J (2007) Hyperthyroidism affects arterial stiffness, plasma NT-pro-B-type natriuretic peptide levels, and subendocardial perfusion in patients with Graves’ disease. Ann Med 9:1–9Google Scholar
  117. 117.
    Arikan S, Tuzcu A, Gokalp D, Bahceci M, Danis R (2007) Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clin Endocrinol (Oxf) 67:202–207Google Scholar
  118. 118.
    Pinelli M, Bindi M, Cassetti G, Moroni F, Pandolfo C, Rosada J, Castiglioni M (2007) Relationship between low T3 syndrome and NT-pro BNP levels in non-cardiac patients. Acta Cardiol 62:19–24PubMedGoogle Scholar
  119. 119.
    Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of UltrasonographyThe Second Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China
  2. 2.Cardiomyopathy ProgramLoma Linda University Medical CenterLoma LindaUSA

Personalised recommendations